STALICLA SA is a biopharmaceutical company developing precision medicines and clinical programs for neurodevelopmental and neuropsychiatric disorders. It uses the DEPI neuro-precision platform, combining multi-omics, patient data and AI to identify subgroups and match patients with drug treatments.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered6
Precision medicine drug development
Precision medicine drug development for neurodevelopmental and neuropsychiatric disorders, with patient-specific subgroup identification, biomarker-based analysis and clinical development of drug candidates.
DEPI Platform
DEPI platform for patient-drug precision matching, multi-omics analysis, patient stratification, responder subgroup identification and prioritization of drug candidates for targeted therapies.
Clinical development of STP1
Clinical development of STP1 as a fixed combination of ibudilast and bumetanide for an ASD subgroup, including completion of Phase 1b and Phase 2 follow-on development.
Clinical development of STP2
Clinical development of STP2 (SFX-01), a stabilized synthetic sulforaphane formulation for neurodevelopmental disorders and an ASD subgroup, with Phase 1 data and preparation for Phase 2.
Clinical development of STP7
Clinical development of STP7 (Mavoglurant) for an ASD subgroup and for cocaine use disorder, with Phase 2 experience and planned or ongoing additional studies.
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.